A review of exenatide as adjunctive therapy in patients with type 2 diabetes.

Compared to placebo: 1) fasting plasma glucose levels were reduced during the 8 hour period of observation ( Table 4 , P < 0.0001); 2) fasting serum insulin concentrations increased in a dose-depend manner during the first 3 hours postadministration of EXE ( Table 4 , P < 0.0001); 3) fasting plasma glucagon concentrations were suppressed although it did not reach statistical significance and 4) rate of acetaminophen plasma concentration exposure was reduced by EXE 0.1 μg/kg compared with placebo significantly (AUC 180 min , mean [± SD]; 25.8 [3.0] μmol/L vs 82.8 [5] μmol/L, respectively).

also in 111,027 other papers

In 3 EXE, placebo-controlled studies, 36 – 38 the risk of hypoglycemia did not achieve significance (OR 3.53 [95% CI 0.92 to 13.61]).

also in 1,397 other papers